Clinical trial
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
NCT00215826 · AIM ImmunoTech Inc., Industry · Completed
Key facts
| NCT number | NCT00215826 |
|---|---|
| Title | Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers |
| Official title | A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Severe Acute Respiratory Syndrome |
| Intervention type | Drug |
| Interventions | Alferon LDO |
| Enrollment | 10 |
| Start date | Nov 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 17, 2013 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: